Please assess the completion status of the following clinical trial:

Trial Title: A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of a primary solid tumor. Patients must have histological verification of malignancy at MSKCC.~* Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP, D9803. Prior to enrollment patient could have been undergoing induction therapy with a similarly myelosuppressive regimen as long as they will be continuing with EFT, MAP, D9803 at the time of study enrollment.~* Patients undergoing treatment with MAP chemotherapy w ho have had ≥ 1 platelet transfusion during induction stage of treatment.~* Total Bilirubin (sum of conjugated + unconjugated) ≤ 3 times institutional upper limit of normal (ULN) for age and ALT/AST ≤ 3 times institutional ULN for age.~* Normal cardiac function:~  * Shortening fraction greater than or equal to 28% by echocardiogram OR Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium- 99m pertechnetate radionuclide cineangiography (MUGA) or echocardiogram.~ * Screening ECG with corrected QT (QTc) interval of \< 470 msec.~ * Timing of cardiac assessment: We will utilize the most recent EKG/ECHO when assessing cardiac function. See section 9.0 for additional details.~* Adequate renal function, defined as an estimated Creatinine Clearance or GFR \>40ml/min or an normal creatine for age (see below)~Serum Creatinine by age:~Age (years) \<6: Maximum Serum Creatinine (mg/dL), Male 0.8, Female 0.8 Age (years) 6 to \<10: Maximum Serum Creatinine (mg/dL), Male 1, Female 1 Age (years) 10 to \<13: Maximum Serum Creatinine (mg/dL), Male 1.2, Female 1.2 Age (years) 13 to \<16: Maximum Serum Creatinine (mg/dL), Male 1.5, Female 1.4 Age (years) \>16: Maximum Serum Creatinine (mg/dL), Male 1.7, Female 1.4~These threshold creatine values were derived from the Scwartz formula estimating GFR, utilizing child length and statured published by the CDC.~Exclusion Criteria:~* Patients with history of hematologic malignancies or allogenic/autogenic stem cell transplant.~* Patients with a currently known predisposition to a myeloid stem cell disorder, myeloid leukemia, and/or bone marrow failure syndrome including, but not limited to:~  * Aplastic anemia~ * Ataxia telangiectasia~ * Bloom syndrome~ * Congenital amegakaryocytic thrombocytopenia~ * Cyclic neutropenia~ * Diamond Blackfan anemia~ * Dyskeratosis congenita~ * Familial AML/MDS syndromes (including ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, SRP72)~ * Fanconi anemia~ * Kostmann disease~ * Li-Fraumeni syndrome~ * Neurofibromatosis~ * Nijmegen breakage syndrome~ * Noonan syndrome~ * Paroxysmal nocturnal hemoglobinuria~ * Pearson syndrome~ * Poland syndrome~ * Rothmund-Thomson syndrome~ * Severe congenital neutropenia~ * Thrombocytopenia absent radii syndrome~ * Trisomy 8~ * Trisomy 21~ * WHIM syndrome~ * Wiskott Aldrich syndrome~ * Xeroderma pigmentosa~* Secondary malignancy in the past 5 years.~* Patients who have previously undergone up-front chemotherapy and have relapsed or progressed through therapy.~* Patients who have received 4 or more cycles of induction chemotherapy for their current malignancy prior to time of enrollment.~* Previous use of romiplostim, eltrombopag, recombinant human TPO, or any other TPO receptor agonist, or any investigational platelet producing agent.~* Patients receiving other investigational agents are not eligible for study entry.~History of uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, active heart failure or pericardial disease.~* Patients with current or prior venous thrombotic event or arterial thrombotic event at time of enrollment will be ineligible for this study.~* Pregnant women/lactating mothers.~* Patients unwilling to use effective contraception method, which includes abstinence.~* Patients with an inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Pediatric Participants (Type: EXPERIMENTAL): Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP or D9803.

Based on this trial design, predict the completion outcome and termination type (if applicable).